Accordingly, the circulation and tissue infiltration of CXCR4+ inflammatory precursors following chemotherapy/immunotherapy (CT/IT) in lung cancer patients represent an additional factor that could be exploited to enhance cancer monitoring and immunotherapy strategies by regulating the immune response against tumors. The gene discussed is CXCR4; the disease is lung carcinoma.